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Prospective Observational Study of Implantable Cardioverter-
Defibrillators in Primary Prevention of Sudden Cardiac Death:
Study Design and Cohort Description
Alan Cheng, MD; Darshan Dalal, MD, PhD; Barbara Butcher, RN; Sanaz Norgard, BS; Yiyi Zhang, PhD; Timm Dickfeld, MD, PhD;
Zayd A. Eldadah, MD, PhD; Kenneth A. Ellenbogen, MD; Eliseo Guallar, MD, DrPH; Gordon F. Tomaselli, MD
Background-—Primary-prevention implantable cardioverter-defibrillators (ICDs) reduce total mortality in patients with severe left
ventricular systolic function. However, only a minority of patients benefit from these devices. We designed the Prospective
Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD) to identify risk factors and enhance our understanding
of the biological mechanisms that predispose to arrhythmic death in patients undergoing ICD implantation for primary prevention
of sudden death.
Methods and Results-—This is a multicenter prospective cohort study with a target enrollment of 1200 patients. The primary end
point is ICD shocks for adjudicated ventricular tachyarrhythmias. The secondary end point is total mortality. All patients undergo a
comprehensive evaluation including history and physical examination, signal-averaged electrocardiograms, and blood sampling for
genomic, proteomic, and metabolomic analyses. Patients are evaluated every 6 months and after every known ICD shock for
additional electrocardiographic and blood sampling. As of December 2011, a total of 1177 patients have been enrolled with more
nonwhite and female patients compared to previous randomized trials. A total of 143 patients have reached the primary end point,
whereas a total of 260 patients died over an average follow-up of 59 months. The PROSE-ICD study represents a real-world cohort
of individuals with systolic heart failure receiving primary-prevention ICDs.
Conclusions-—Extensive electrophysiological and structural phenotyping as well as the availability of serial DNA and serum
samples will be important resources for evaluating novel metrics for risk stratification and identifying patients at risk for arrhythmic
sudden death.
Clinical Trial Registration-—URL: http://clinicaltrials.gov/ Unique Identifier: NCT00733590. ( J Am Heart Assoc. 2013;2:
e000083 doi: 10.1161/JAHA.112.000083)
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S udden cardiac death (SCD) is the most common cause ofdeath in the United States, affecting >300 000 individuals
yearly.1–3 SCD is most often the result of ventricular tachyar-
rhythmias that occur secondary to a complex interplay between
a susceptible myocardial substrate typically affected by ischemic
or nonischemic cardiomyopathy and a transient trigger.4 Primary
prevention implantable cardioverter-defibrillators (ICDs) have
been shown to reduce total mortality in high-risk patients.5,6
Early efforts aimed at identifying individuals at greatest risk for
SCD included the use of several invasive and noninvasive metrics
including electrophysiology studies, signal-averaged electrocar-
diograms, heart rate variability, heart rate turbulence, measure-
ment of microvolt T-wave alternans, and measurements of
repolarization lability.7–11 Although some showed early promise,
the most robust metric has been reductions in the left ventricular
ejection fraction. Unfortunately, this metric is neither highly
sensitive nor specific and does not take into consideration other
genetic or electrophysiological determinants for arrhythmogen-
esis. As a result, there is substantial interest in identifying more
reliable predictors that could help to discriminate which patients
are most likely to benefit.
The Prospective Observational Study of Implantable Cardio-
verter-Defibrillators (PROSE-ICD) is a multicenter prospective
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observational study of patients undergoing ICD or cardiac
resynchronization therapy (CRT) implantation for primary
prevention of SCD. Its aim is to identify risk factors and
enhance our understanding of the biological mechanisms that
predispose to arrhythmic SCD, with the hope of developing a
paradigm to identify individuals who stand to benefit the most
and the least from primary prevention ICDs. Patients undergo
extensive phenotyping and biobanking of DNA and serum at the
time of implantation, at 6-month intervals throughout follow-up,
and after ICD shock events. This article presents an overview of
the PROSE-ICD design, a descriptive analysis of the demo-




PROSE-ICD is a multicenter prospective cohort study (clini-
caltrials.gov identifier NCT00733590) of patients undergoing
ICD implantation for primary prevention of SCD on the basis
of criteria outlined in current practice guidelines.12 The study
is being conducted at 4 centers in the United States: the
Johns Hopkins Hospital and Bayview Medical Center, Balti-
more, MD; the University of Maryland Hospital, Baltimore, MD;
the Washington Hospital Center, Washington, DC; and the
Virginia Commonwealth University Hospital, Richmond, VA.
The study population includes primary prevention ICD or
CRT recipients between 18 and 80 years of age fulfilling 1 of
2 criteria: (1) ischemic cardiomyopathy (myocardial infarction
occurring >40 days prior to implant and no revascularization
within the past 90 days) with an ejection fraction of ≤30% and
(2) ischemic or nonischemic cardiomyopathy with an ejection
fraction ≤35% and stable heart failure symptoms (New York
Heart Association [NYHA] Class II to III) on optimal
pharmacotherapy (Table 1). In addition, CRT patients were
included if they demonstrated an ejection fraction of ≤35%,
NYHA Class III to IV heart failure symptoms, and a QRS width
of >120 ms. No requirement is specified regarding QRS
morphology. Patients are excluded if the ICD or CRT was
implanted for secondary prevention, if they had a permanent
pacemaker or a preexisting class 1 indication for pacemaker
implantation, NYHA Class IV heart failure (unless they were
undergoing implantation of a CRT device), or fulfillment of any
Class III indication for primary prevention ICD implantation as
outlined in current practice guidelines.12 Patients are enrolled
prior to ICD implantation but considered part of the study
cohort only after successful ICD placement. PROSE-ICD
recruitment started in December 2003 and is ongoing with
a target enrollment of 1200. This study has been approved by
the institutional review boards of all participating hospitals. All
participants have provided written informed consent.
Preimplantation Assessment and Serum
Processing
At enrollment and prior to ICD implantation, each patient
undergoes a comprehensive history and cardiovascular phys-
ical examination, electrocardiographic (ECG) evaluation,
cardiac imaging to assess ejection fraction, and a blood
draw. ECGs are recorded digitally (Norav Medical, Ontario,
Canada) and include a standard 12-lead recording as well as a
high-resolution 5-minute rhythm strip using 3 orthogonal
leads. Adjudicated automated readings of the 12-lead ECGs
are performed for rhythm determination and conduction
abnormalities. The rhythm strip is analyzed by computer-
based algorithms for signal averaging and for measuring heart
rate and QT variability parameters. Heart rate and QT
variability analyses are performed in the time and frequency
domains after excluding ECGs exhibiting frequent atrial or
Table 1. Criteria for Inclusion in the PROSE-ICD Cohort
Inclusion Criteria Exclusion Criteria
18 to 80 years of age ICD implantation for secondary prevention
History of acute myocardial infarction ≥40 days old (confirmed by persistent pathologic Q
waves on ECG, clinical reports of CPK-MB >3 times the upper limit of normal, or a fixed
perfusion defect on nuclear imaging) with an ejection fraction (EF) ≤30% and no history
of revascularization within the last 3 months.
Patients with a permanent pacemaker or a preexisting class 1
indication for pacemaker implantation
Patients with New York Heart Association Class IV heart failure
(unless undergoing CRT implantation)
History of ischemic or nonischemic left ventricular systolic dysfunction with stable NYHA
Class II to III heart failure symptoms for ≥3 months on optimal pharmacotherapy and an
EF ≤35%. For CRT patients, EF ≤35%, QRS >120 ms, NYHA Class III to IV heart failure
symptoms on optimal pharmacotherapy
Patients with history of a confirmed myocardial within 40 days of
implant or revascularization within the last 3 months
Patients fulfilling class III indications for primary prevention ICD
implantation
Unsuccessful ICD implantation
Patient unable or unwilling to provide informed consent
PROSE-ICD indicates Prospective Observational Study of Implantable Cardioverter-Defibrillators; ECG, electrocardiogram; CRT, cardiac resynchronization therapy; NYHA, New York Heart
Association; CPK-MB, creatine kinase MB band.
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ventricular ectopy, atrial fibrillation, or ventricular pacing. In
addition, patients with bundle branch block are excluded from
QT variability analyses.
The blood draw and processing are standardized. Peripheral
blood is collected and allowed to stand at room temperature for
1 hour to minimize the variance in the time from collection to
processing. Blood in nonanticoagulated (red-top) tubes is
centrifuged at 1500 rpm for 5 minutes. The serum is then
transferred into tubes containing 200- to 500-lL aliquots,
frozen in liquid nitrogen and stored at 80°C. Buffy coats are
also collected and after a similar low-speed spin, are transferred
into 100-lL aliquots prior to 80°C storage. Routine clinical
laboratory tests are performed and the specific tests deter-
mined by the treating physicians. Additional blood is collected
for future analysis as part of this study. There are no
prespecified blood tests performed on the study samples, but
biomarker, metabolomic, and genomic analyses are planned.
The specific platforms for genetic testing are not prespecified
but will be focused on analyzing large numbers of single-
nucleotide polymorphisms among other things.
ICD Implantation and Programmed Stimulation
Device implantation is performed only in patients without
clinical evidence of active myocardial ischemia, decompensat-
ed heart failure, or infection. All procedures are performed in the
standard clinical fashion either with conscious sedation or
general anesthesia. In cases of CRT devices, left ventricular
pacing leads are targeted to a lateral or posterolateral branch of
the great cardiac vein. The final location of the left ventricular
pacing lead is assessed using saved fluoroscopic images at the
time of device implantation. Toward the end of the procedure,
physicians are encouraged to perform programmed stimulation
through the device. Programmed ventricular stimulation is
performed at 2 drive trains (350 and 500 ms) with up to 3
extrastimuli. The minimum extrastimulus coupling interval is
200 ms.When the ventricular effective refractory period (VERP)
is reached for a given extrastimulus, the coupling interval of the
preceding extrastimulus is decremented by 10-ms intervals
until VERP is reached or a coupling interval of 200 ms. This
process is repeated for all extrastimuli. Morphology and cycle
lengths of all sustained ventricular arrhythmias induced are
recorded. Data on ICD generator and leads implanted, tachy-
cardia therapy cutoff rates and therapies programmed, use of
supraventricular arrhythmia discriminators, and sensitivity
settings are also noted.
Patient Follow-Up Visits, Adjudication of ICD
Arrhythmias, and Censoring Events
Patients are evaluated every 6 months after implantation and
soon after any ICD shock event reported by the patient
(Figure). At each visit, study participants undergo a focused
cardiac history and physical exam, digital ECG recording, and
blood draws as described above. The ICD is also interrogated
for device performance metrics and recorded arrhythmic
events. All stored electrograms from delivered ICD therapies
are collected and adjudicated by 2 clinical cardiac electrophy-
siologists blinded to patient identifiers or other clinical
information. For every recorded event, each electrophysiolo-
gist independently determines the rhythm at the time of initial
detection and after therapy delivery. If there is disagreement
with the diagnosed rhythm at the time of initial detection, the
episode is then reviewed by a third electrophysiologist for
final adjudication. Patients who miss their scheduled visits or
are unable to return to the enrolling center for follow-up are
contacted by phone. During these phone interviews, current
health status and medication use are updated as well as any
interim cardiovascular-related events. Every effort is made to
obtain source documentation of pertinent hospitalizations.
Primary and Secondary End Points
The primary outcome of PROSE-ICD is ICD shocks for adjudi-
cated ventricular tachyarrhythmias. The secondary outcome is
all-cause mortality. It is expected that some patients will have
multiple ICD shocks for ventricular tachyarrhythmias. For the
purposes of the analysis, the first confirmed instance will be
used unless it was preceded by an ICD shock for supraventric-
ular tachyarrhythmias within a 24-hour period. We are qualify-
ing this definition because we cannot be absolutely sure that
Figure. Study design of PROSE-ICD. Baseline measurements
include comprehensive history, digitized signal-averaged ECG, 12-
lead baseline ECG, blood collection, and in some patients, cardiac
computed tomography (CT) with contrast or cardiac magnetic
resonance imaging (MRI) with gadolinium-based delayed hyperen-
hancement. Patients are routinely evaluated either in person or via
phone call every 6 months. Soon after an ICD shock, patients are
encouraged to return to the clinic for further evaluation. At the visit
after the shock, the device is interrogated and the event downloaded
for adjudication. A 12-lead ECG, signal-averaged ECG, and blood
collection are also collected again. PROSE-ICD indicates Prospective
Observational Study of Implantable Cardioverter-Defibrillators; ECG,
electrocardiogram; NIPS, noninvasive programmed stimulation
through the ICD; MI/HF, index myocardial infarction or initial
diagnosis of heart failure; SAECG, signal-averaged ECG; HRv, heart
rate variability analysis; QTv, QT interval variability analysis.
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therewas no residual effect of the first “inappropriate” shock on
the development of the subsequent “appropriate” shock.
Deaths are ascertained by phone contact with the next of kin
and by searches of the National Death Index. Next of kin
interviews regarding the circumstances surrounding the death,
death certificates, and medical documentation around the time
of death including ICD interrogations whenever possible are
collected. This information is subsequently reviewed and
adjudicated by 2 independent cardiologists. Each death event
is adjudicated on the basis of modified Hinkle–Thaler criteria.13
Statistical Analysis
Patients are considered part of the cohort after successful
ICD implant. For time-to-event analysis for the primary end
point, patients are censored at the time of death, ICD
explantation, left ventricular assist device implantation or
heart transplantation, or at the last date of contact among
those still alive. For time-to-event analysis for all-cause
mortality (secondary end point), follow-up is censored at the
time of ICD explantation, left ventricular assist device
implantation or heart transplantation, or at the last date of
contact or the date of death in the National Death Index.
These events are selected on the basis of their likelihood of
altering the patient’s underlying cardiac disease process and
hence their risk for ICD shocks. The Kaplan–Meier method will
be used to estimate the cumulative incidence of these events.
Incidence rates for a given event will be calculated by taking
the ratio of the total number of events and the total number of
person-years of follow-up contributed by cohort participants.
Hazard ratios of study outcomes adjusted for other participant
characteristics will be estimated using proportional hazards
regression models.
Sample Size and Power Estimates
On the basis of prior randomized clinical trials,5,6 the
annualized primary end point event rate is estimated at 6%.
Annual loss from censoring and losses to follow-up are
estimated at 5%. We calculate that a target enrollment of
1200 patients will result in 362 primary end point events by
the end of follow-up and will allow us to detect an estimated
hazard ratio of ≥1.85 when comparing extreme quartiles of an
independent predictor of ICD shocks with 80% power and a
probability of type I error of 5% (2-sided).
Results
Study Population
As of December 31, 2011, PROSE-ICD has enrolled 1177
patients. Although their characteristics are similar to the
patients enrolled in MADIT II and SCD-HeFT, there are some
notable differences (Table 2). Overall, individuals are predom-
inantly male with a relatively balanced distribution of cardio-
myopathy etiology. The meanSD ejection fraction is 238%,
with a majority of individuals exhibiting New York Heart
Association Class I to II heart failure symptoms. The
proportion of nonwhite patients is 43%. The baseline preva-
lence of hypertension and diabetes is 63% and 35%, respec-
tively. Overall, there are high rates of heart failure medication
usage at the time of enrollment with 90% of individuals taking
b-blockers and 88% taking angiotensin-converting enzyme
inhibitors (ACE-Is) or angiotensin receptor blockers. Enroll-
ment at the 4 sites reveals differences in demographics
across the sites (Table 3). The Johns Hopkins University site
shows the highest proportion of white participants and a
lower prevalence of diabetes and hypertension. There is no
difference in either the percentage of patients with ischemic
cardiomyopathy or significant differences in left ventricular
ejection fraction or NYHA class function across the sites. ICD
programming is left to the discretion of the implanting
physician. To date, the average cutoff zone is 184.8 beats per
minute (bpm) with a standard deviation of 15.4 bpm.
Table 2. Qualitative Comparison of Demographics and
Clinical Characteristics of PROSE-ICD (as of December 31,
2011) With ICD Arms of MADIT-II and SCD-HeFT Trial. Total
Number of Patients Enrolled in MADIT II and SCD-HeFT Are
1232 and 2521, Respectively. Description Below Only








Age, y 6113 6410 60.1*
Sex, male 73 84 77
Race, nonwhite 43 0 23
Smoking 67 80 —
Diabetes 35 33 31
Hypertension 63 53 55
LVEF 238 235 24*
NYHA class
Class I 17 35 0
Class II 43 35 70
Class III 38 25 30




Data expressed as meanSD or percentage, unless otherwise indicated. PROSE-ICD
indicates Prospective Observational Study of Implantable Cardioverter-Defibrillators;
MADIT-II, Multicenter Automatic Defibrillator Implantation Trial-II; SCD-HeFT, Sudden
Cardiac Death in Heart Failure Trial; LVEF, left ventricular ejection fraction; NYHA,
New York Heart Association.
*Median.
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Current Study End Points
As of December 31, 2011, a total of 234 patients have
experienced an ICD shock over an average of 5923 months
of follow-up. Among them, 143 experienced ICD shocks for
ventricular tachyarrhythmias.
Discussion
Sudden cardiac death remains the most common mode of
death in the United States and other developed countries. The
use of primary prevention ICDs has been shown to reduce
total mortality in individuals with severe dilated cardiomyop-
athy, but only a minority of patients receive appropriate ICD
therapies. Furthermore, current rates of periprocedural com-
plications,14 device malfunctions15 and the incidence of
inappropriate ICD shocks16,17 have led some to question
whether the benefits outweigh the risks.18,19 Hence, it is ever
more important to accurately identify individuals who stand to
benefit the most from this intervention.
The optimal strategy for risk stratification of primary
prevention individuals at greatest risk for sudden death is still
poorly defined. Current strategies rely in large measure on the
left ventricular ejection fraction, but limited sensitivity and
specificity have led to the proposal of other noninvasive
measurements20 such as microvolt T-wave alternans,21 mag-
netic resonance imaging,22 serum-based biomarkers,23 or a
combination of these metrics.24 Additional validation in large
cohorts will be required prior to widespread adoption of these
techniques in clinical practice.25
PROSE-ICD was conceived with the overall aim of better
understanding the biological pathways predisposing to SCD.
We will use extensive phenotyping of study participants
including genetic, proteomic, metabolomic, electrophysiolog-
ical, and epidemiological markers to help establish a risk
stratification schema that will identify patients at highest and
lowest risk for SCD. This study is one of the largest, most
extensively phenotyped cohorts of patients undergoing
prophylactic ICD implantation. The stringent enrollment
criteria and phenotyping accompanied by routine data-quality
checks will provide good internal and external validity of the
data.
Although the current demographic makeup of this study is
similar to previous landmark clinical trials,5,6 there are some
differences. First, the percentages of women and nonwhites are
27% and 43%, respectively. This is in contrast to patients from
Table 3. Demographics and Clinical Characteristics of PROSE-ICD by Enrolling Center as of December 31, 2011
Characteristic JHU (n=730) UMD (n=86) VCU (n=72) WHC (n=289) Total (n=1177)
Age, y 6013 6214 5813 6212 6113
Sex, male 72 82 64 75 73
Race, white 67 40 39 40 57
Smoking 69 65 44 68 67
Diabetes 30 44 43 42 35
Hypertension 51 81 76 83 63
LVEF, % 228 239 236 247 238
NYHA class
Class I 17 7 14 23 17
Class II 36 45 49 60 43
Class III 46 48 36 17 38
Class IV 1 0 0 0 1
Cardiomyopathy, ischemic 52 55 51 59 54
Medication use
Beta-blocker 88 87 86 92 90
ACE inhibitor/ARB 88 88 85 87 88
Statin 66 65 65 79 70
Antiarrhythmics 9 6 3 12 10
Aldosterone antagonist 25 27 29 23 25
Values expressed as meanSD or frequency (%). PROSE-ICD indicates Prospective Observational Study of Implantable Cardioverter-Defibrillators; JHU, Johns Hopkins University; UMD,
University of Maryland; VCU, Virginia Commonwealth University, WHC, Washington Hospital Center; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; ACE,
angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
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the SCD-HeFT study, whose enrollment was 23% women and
23% nonwhite subjects. PROSE-ICD will thus provide insights
into the effects of sex and race that cannot be obtained from
other studies because of enrollment limitations. Second, the
use of heart failure medications at the time of enrollment is
optimal, with 90% of individuals on b-blockers and 88% on
ACE-Is. Whether outcomes in patients with ICDs are modulated
by optimal heart failure medications remains to be seen. Third,
this study reflects current clinical practice patterns and did not
require implanting physicians to adopt a prespecified device
programming strategy (eg, utilization of antitachycardia pacing,
programming several tachyarrhythmic therapy zones). Hence,
the findings from this study stand to better reflect how patients
in the general population do over time and provide us with
real-world outcomes. Lastly, the plans for extensive clinical
phenotyping and blood collection will allow us to prospectively
follow patients and potentially identify novel markers of risk for
arrhythmic events.
Potential Limitations
This study is a prospective, observational study, and inherent
limitations of this design as well as variables not currently
measured at the time of enrollment may have an effect on the
interpretability of the findings. In addition, we have focused on
enrollment of individuals with evidence of systolic heart
failure. Hence, findings from this study may not apply to the
smaller group of individuals with preserved systolic function
undergoing primary prevention ICD implantation such as long
QT syndrome, early-stage cardiac sarcoidosis, and other
inherited genetic channelopathies. Despite these limitations,
we believe that the findings from this study will have
significant implications on SCD risk assessment and man-
agement as this cohort represents the largest, most exten-
sively phenotyped group of individuals undergoing ICD
implantation for primary prevention of sudden death.
Conclusions
The PROSE-ICD study represents a typical cohort of patients
receiving ICDs for primary prevention of SCD on the basis of
current practice guidelines. Although the clinical demographics
appear to be similar to previously published randomized trials,
there are some notable differences. PROSE-ICD will allow us to
identify subgroups that stand to benefit the most from these
devices and perhaps to craft novel strategies for risk stratifi-
cation of patients potentially at risk for sudden death.
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